At the time of writing, Adaptimmune Therapeutics Plc ADR [ADAP] stock is trading at $1.39, up 6.92%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADAP shares have gain 18.80% over the last week, with a monthly amount glided 67.17%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on May 30, 2024, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $3.15. Previously, Bryan Garnier started tracking the stock with Buy rating on March 24, 2023, and set its price target to $3.60. On January 03, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. Mizuho upgraded its rating to a Buy but stick to its price target of $9 on November 09, 2022. Barclays initiated its recommendation with a Underweight and recommended $4 as its price target on May 28, 2021. Mizuho started tracking with a Neutral rating for this stock on April 22, 2020, and assigned it a price target of $3. In a note dated August 02, 2019, Guggenheim downgraded an Neutral rating on this stock.
For the past year, the stock price of Adaptimmune Therapeutics Plc ADR fluctuated between $0.42 and $2.05. Currently, Wall Street analysts expect the stock to reach $2.54 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $1.39 at the most recent close of the market. An investor can expect a potential return of 82.73% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
According to Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP], the company’s sales were 18.33M for trailing twelve months, which represents an -88.19% plunge. Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -10.59%, Pretax Profit Margin comes in at -9.06%, and Net Profit Margin reading is -8.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -2.35 and Total Capital is -1.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3167 points at the first support level, and at 1.2433 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4417, and for the 2nd resistance point, it is at 1.4933.
Ratios To Look Out For
It is important to note that Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] has a current ratio of 2.81. On the other hand, the Quick Ratio is 2.81, and the Cash Ratio is 2.12. Considering the valuation of this stock, the price to sales ratio is 19.38, the price to book ratio is 14.57.
Transactions by insiders
Recent insider trading involved Piccina Cintia, Chief Commercial Officer, that happened on Jun 18 ’24 when 24531.0 shares were sold. Chief Executive Officer, Rawcliffe Adrian completed a deal on Jan 17 ’24 to sell 30080.0 shares. Meanwhile, Chief Operating Officer Bertrand William C JR sold 18908.0 shares on Jan 17 ’24.
